BioCryst Pharmaceuticals is trading at $8.70, up 9.43% in pre-market, with no confirmed company-specific catalyst for the October 7 move.
- The price is compared with the October 6 close of $7.95.
- The company announced a seven-member scientific advisory board on October 5; available coverage does not establish it as the reason for the gain.
- The broader market context is weaker and does not explain the move either.